CenterBook Partners LP decreased its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 578,828 shares of the company’s stock after selling 57,327 shares during the period. CenterBook Partners LP’s holdings in Compass Pathways were worth $3,994,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC bought a new position in Compass Pathways during the third quarter worth about $41,000. BIT Capital GmbH bought a new position in Compass Pathways during the third quarter worth about $54,000. Northeast Financial Consultants Inc bought a new position in Compass Pathways during the second quarter worth about $59,000. Raymond James Financial Inc. lifted its stake in Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the period. Finally, U.S. Capital Wealth Advisors LLC bought a new position in Compass Pathways during the fourth quarter worth about $104,000. Institutional investors own 46.19% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have recently issued reports on CMPS shares. UBS Group set a $18.00 target price on shares of Compass Pathways in a research note on Thursday, May 7th. Wolfe Research started coverage on shares of Compass Pathways in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. Maxim Group lifted their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Finally, Jefferies Financial Group upgraded shares of Compass Pathways to a “strong-buy” rating in a research note on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and an average price target of $21.36.
Compass Pathways Stock Performance
NASDAQ:CMPS opened at $11.73 on Tuesday. Compass Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $14.76. The firm has a 50 day moving average of $9.11 and a 200-day moving average of $7.45. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.58 billion, a P/E ratio of -3.72 and a beta of 2.50.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, sell-side analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current fiscal year.
Compass Pathways Profile
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
Featured Stories
- Five stocks we like better than Compass Pathways
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report).
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
